生物兵器防衛の世界市場分析:製品別(炭疽菌、天然痘、ボツリヌス中毒、放射線/核、エボラ、出血熱)、セグメント予測、-2020

Grand View Researchが発行した調査報告書(GVIEW707118)
◆英語タイトル:Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020
◆商品コード:GVIEW707118
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2015年1月1日
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,700 ⇒換算¥531,100見積依頼/購入/質問フォーム
Multi UserUSD8,000 ⇒換算¥904,000見積依頼/購入/質問フォーム
Global/corporate LicenseUSD10,500 ⇒換算¥1,186,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、生物兵器防衛の世界市場について調査・分析し、生物兵器防衛の世界市場動向、生物兵器防衛の世界市場規模、市場予測、セグメント別生物兵器防衛市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Global biodefense market is expected to reach USD 13.33 billion by 2020. Growing R&D investments in the field of biotechnology coupled with increasing threat of bioterrorism and disease outbreaks is expected to drive market growth during the forecast period. Furthermore, presence of favorable government initiatives for instance the Emergency Use Authorization (EUA) is expected to boost market growth. This provision allows products to be marketed without an FDA approval in an emergency. Initiatives undertaken by the governments of developing nations for strengthening their respective biodefense product portfolio is expected to fuel future market growth.
Biodefense against anthrax accounted for the largest market share owing to its inclusion in the class A highest priority pathogen category. This classification has resulted in the presence of extensive R&D investments aimed at new product development for strengthening national stockpiles. The global biodefense against anthrax was valued at over USD 2.0 billion in 2013.

Further key findings from the study suggest:

North American was the most revenue generating region in 2013. Majority of the funding programs are organized by the U.S. based government and private establishments. Moreover, these establishments cater to procurement needs of foreign markets.
The market is majorly governed by the initiatives undertaken in the U.S. The country is the largest revenue contributor and is expected to maintain its market position throughout the forecast period. Moreover, funding received by manufacturers under projects such as BioShield is expected to significantly boost demand over the next six years.
Developed European countries such as Germany and the UK have designated funding policies in place pertaining to biodefense. In Switzerland, there is no set biodefense definition but the NBC (nuclear, biological, chemical) protection and research is carried out in Spiez Laboratory of Federal office for Civil Protection, within the Federal Department of Defense. A total of 12 civilian facilities operate under the Swiss biodefense program.
Key players of this market include Emergent BioSolutions, SIGA Technologies, Xoma Corporation and PharmAthene.
Mergers and acquisitions and participating in government tenders are two key sustainability strategies adopted by market players. For instance, in December, 2014, Emergent BioSolutions announced that it had acquired the EV-035 series of molecules from Evolva Holding SA. The acquisition will further strengthen the company’s biodefense line of products.
For the purpose of this study, Grand View Research has segmented the global biodefense market on the basis of product and region:

Global Biodefense Product Outlook (Revenue, USD Million, 2012 – 2020)
• Anthrax
• Smallpox
• Botulism
• Radiation/Nuclear defense
• Others
Biodefense Regional Outlook (Revenue, USD Million, 2012 – 2020)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• RoW
• Brazil

【レポートの目次】

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Biodefense Industry Outlook
2.1 Market Segmentation
2.2 Market size and growth prospects
2.3 Biodefense – Market dynamics
2.3.1 Market driver analysis
2.3.1.1 Presence of favorable government initiatives
2.3.1.1.1 Emergency Use Authorization of Medical Products
2.3.1.1.2 Project BioShield Act
2.3.2 Market Restraint Analysis
2.3.2.1 Low market penetration in developing and underdeveloped countries
2.4 Key Opportunities Prioritized
2.6 Biodefense – PESTEL analysis
2.7 Market scenario by type
2.7.1 Biological Defense
2.7.2 Chemical Defense
2.7.2.1 Chemical defense: Product pipeline
2.7.3 Nuclear/Radiological Defense
2.7.3.1 Nuclear/radiological defense: Product pipeline analysis
Chapter 3 Biodefense Product Outlook
3.1 Biodefense market share by product, 2013 & 2020
3.2 Anthrax
3.2.1 Biodefense against anthrax market, 2012 – 2020 (USD Million)
3.3 Smallpox
3.3.1 Biodefense against smallpox market, 2012 – 2020 (USD Million)
3.4 Botulism
3.4.1 Biodefense against botulism market, 2012 – 2020 (USD Million)
3.5 Radiation/ nuclear defense
3.5.1 Biodefense against radiation/nuclear defense market, 2012 – 2020 (USD Million)
3.6 Others
3.6.1 Biodefense against other threats market, 2012 – 2020 (USD Million)
Chapter 4 Biodefense Regional Outlook
4.1 Biodefense market share by region, 2013 & 2020
4.2 North America
4.2.1 North America biodefense market, 2012 – 2020 (USD Million)
4.2.2 U.S. biodefense market, 2012 – 2020 (USD Million)
4.2.3 U.S. biodefense market,2012-2020 (USD Million)
4.2.3.1 U.S. biodefense market, by scenario, 2012 – 2020 (USD Million)
4.2.4 U.S. biodefense market, by source, 2012 – 2020 (USD Million)
4.2.4.1 Federal Agencies
4.2.4.1.1 BioShield Act
4.2.4.1.2 Department of Health and Human Services (HHS)
4.2.4.1.3 Department of Defense (DoD)
4.2.4.1.4 Department of Homeland Security
4.2.4.1.5 Department of Agriculture
4.2.4.1.6 Environmental Protection Agency
4.2.4.1.7 Department of Commerce
4.2.4.2 Other Agencies
4.2.5 Canada biodefense market, 2012 – 2020 (USD Million)
4.3 Europe
4.3.1 Europe biodefense market, 2012-2020 (USD Million)
4.3.2 Germany biodefense market, by product,2012-2020(USD Million)
4.3.3 Germany biodefense market, 2012-2020 (USD Million)
4.3.4 UK biodefense market, by product, 2012-2020 (USD Million)
4.3.5 UK biodefense market, 2012-2020 (USD Million)
4.4 Asia Pacific
4.4.1 Asia Pacific biodefense market, 2012-2020 (USD Million)
4.4.2 Japan biodefense market, 2012-2020 (USD Million)
4.4.3 Japan biodefense market, 2012-2020(USD Million)
4.4.4 China biodefense market, 2012-2020 (USD Million)
4.5 RoW
4.5.1 RoW biodefense market, 2012-2020 (USD Million)
Chapter 5 Competitive Landscape
5.1 Xoma Corporation
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 PharmAthene
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Emergent Biosolutions
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Product Benchmarking
5.3.4 Strategic Initiatives
5.4 Dynavax Technologies Inc.
5.4.1 Company Overview
5.4.2 Financial Performance
5.4.3 Product Benchmarking
5.4.4 Strategic Initiatives
5.5 SIGA Technologies
5.5.1 Company Overview
5.5.2 Financial Performance
5.5.3 Product Benchmarking
5.5.4 Strategic Initiatives
5.6 Elusys Therapeutics
5.6.1 Company Overview
5.6.2 Financial Performance
5.6.3 Product Benchmarking
5.6.4 Strategic Initiatives
5.7 Ichor Medical Systems Inc.
5.7.1 Company Overview
5.7.2 Financial Performance
5.7.3 Product Benchmarking
5.7.4 Strategic Initiatives
5.8 DynPort Vaccine Company LLC
5.8.1 Company Overview
5.8.2 Financial Performance
5.8.3 Product Benchmarking
5.8.4 Strategic Initiatives
5.9 Cleveland BioLabs, Inc.
5.9.1 Company Overview
5.9.2 Financial Performance
5.9.3 Product Benchmarking
5.9.4 Strategic Initiatives
5.10 Bavarian Nordic
5.10.1 Company Overview
5.10.2 Financial Performance
5.10.3 Product Benchmarking
5.10.4 Strategic Initiatives
5.11 Achaogen
5.11.1 Company Overview
5.11.2 Financial Performance
5.11.3 Product Benchmarking
5.11.4 Strategic Initiatives
5.12 Nanotherapeutics, Inc.
5.12.1 Company Overview
5.12.2 Financial Performance
5.12.3 Product Benchmarking
5.12.4 Strategic Initiatives
5.13 Alnylam Pharmaceuticals
5.13.1 Company Overview
5.13.2 Financial Performance
5.13.3 Product Benchmarking
5.14 Major list of biodefense contracts, by market player
Chapter 6 Methodology and Scope
6.1 Research Methodology
6.2 Research Scope & Assumptions
6.3 List of Data Sources

List of Tables

TABLE 1 Biodefense Market – Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Biodefense market, by region, 2012 – 2020 (USD Million)
TABLE 3 U.S. biodefense market, by product, 2012 – 2020 (USD million)
TABLE 4 Biodefense – Key market driver analysis
TABLE 5 Biodefense – Key market restraint analysis
TABLE 6 Biological defense: Product pipeline
TABLE 7 List of pipeline products: Anthrax
TABLE 8 List of pipeline products: Smallpox
TABLE 9 List of pipeline products: Botulism
TABLE 10 List of pipeline products: Radiation/nuclear defense
TABLE 11 List of pipeline products: Other threats
TABLE 12 U.S. biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 13 U.S. biodefense market, by scenario, 2012 – 2020 (USD Million)
TABLE 14 U.S. biodefense market, by source, 2012 – 2020 (USD Million)
TABLE 15 Programs under HHS:
TABLE 16 Programs under DoD:
TABLE 17 Programs under department of homeland security
TABLE 18 Programs under department of agriculture
TABLE 19 Canada biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 20 Germany biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 21 Biodefense program licensed manufacturing sites in the UK
TABLE 22 UK biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 23 Japan biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 24 China biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 25 RoW biodefense market, by product, 2012 – 2020 (USD Million)
TABLE 26 Major list of biodefense contracts, by market player

List of Figures

FIG. 1 Biodefense: Market segmentation
FIG. 2 Global biodefense market, 2012 – 2020 (USD Million)
FIG. 3 Biodefense: Market dynamics
FIG. 4 Key opportunities prioritized
FIG. 5 Biodefense market – Porter’s analysis
FIG. 6 Biodefense market – PESTEL analysis
FIG. 7 Biodefense market share by product, 2013 & 2020
FIG. 8 Global anthrax biodefense market, 2012 – 2020 (USD Million)
FIG. 9 Global smallpox biodefense market, 2012 – 2020 (USD Million)
FIG. 10 Global botulism biodefense market, 2012 – 2020 (USD Million)
FIG. 11 Global radiation/nuclear defense market, 2012 – 2020 (USD Million)
FIG. 12 Global biodefense market for other threats, 2012 – 2020 (USD Million)
FIG. 13 Biodefense market share by region, 2013 & 2020
FIG. 14 North America biodefense market , 2012 – 2020 (USD Million)
FIG. 15 U.S. biodefense market , 2012 – 2020 (USD Million)
FIG. 16 Canada biodefense market , 2012 – 2020 (USD Million)
FIG. 17 Europe biodefense market , 2012 – 2020 (USD Million)
FIG. 18 Germany biodefense market , 2012 – 2020 (USD Million)
FIG. 19 UK biodefense market , 2012 – 2020 (USD Million)
FIG. 20 Asia Pacific biodefense market , 2012 – 2020 (USD Million)
FIG. 21 Japan biodefense market , 2012 – 2020 (USD Million)
FIG. 22 China biodefense market , 2012 – 2020 (USD Million)
FIG. 23 RoW biodefense market , 2012 – 2020 (USD Million)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 生物兵器防衛の世界市場分析:製品別(炭疽菌、天然痘、ボツリヌス中毒、放射線/核、エボラ、出血熱)、セグメント予測、-2020(Biodefense Market Analysis By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear, Ebola, Hemorrhagic Fever) And Segment Forecasts To 2020)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆